No evident disease activity at 24 weeks in patients with relapsing MS treated with interferon β-1a SC vs. interferon β-1a im in the EVIDENCE study

Authors
Category Primary study
ConferenceMultiple Sclerosis
Year 2014
This article has no abstract
Epistemonikos ID: df214d11ad8c3cb7ae48889c4f5588b4283d369d
First added on: Apr 30, 2026